David Packham

Erratum to: Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Exploratory Analyses from Three Randomized, Multi-Dose, Placebo-Controlled Trials.

Simon D Roger, Bruce S Spinowitz, Edgar V Lerma, Steven Fishbane, Stephen R Ash, Julian G Martins, Carol Moreno Quinn, David K Packham

Journal article  |  2021  |  Nephrol Dial Transplant

In the originally published version of this manuscript, although all tables and figures were correct, several correspondingmainten..

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.

Zien Zhou, Meg J Jardine, Qiang Li, Brendon L Neuen, Christopher P Cannon, Dick de Zeeuw, Robert Edwards, Adeera Levin, Kenneth W Mahaffey, Vlado Perkovic, Bruce Neal, Richard I Lindley, undefined CREDENCE Trial Investigators*

Journal article  |  2021  |  Stroke

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases..

Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study

Simon D Roger, Philip T Lavin, Edgar Lerma, Peter A McCullough, Javed Butler, Bruce S Spinowitz, Stephan von Haehling, Mikhail Kosiborod, June Zhao, Steven Fishbane, David K Packham

Journal article  |  2021  |  NEPHROLOGY DIALYSIS TRANSPLANTATION

BACKGROUND: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for the treatment of adults w..

Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE

Simon D Roger, Bruce S Spinowitz, Edgar Lerma, Bhupinder Singh, David K Packham, Ayman Al-Shurbaji, Mikhail Kosiborod

Journal article  |  2019  |  AMERICAN JOURNAL OF NEPHROLOGY

BACKGROUND: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for treatment of hyperkalemia..

Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease

Peter Rossing, Geoffrey A Block, Melanie P Chin, Angie Goldsberry, Hiddo JL Heerspink, Peter A McCullough, Colin J Meyer, David Packham, Pablo E Pergola, Bruce Spinowitz, Stuart M Sprague, David G Warnock, Glenn M Chertow

Journal article  |  2019  |  KIDNEY INTERNATIONAL

Bardoxolone methyl attenuates inflammation by inducing nuclear factor erythroid-derived 2-related factor 2 and suppressing nuclear..

Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia A 12-Month Phase 3 Study

Bruce S Spinowitz, Steven Fishbane, Pablo E Pergola, Simon D Roger, Edgar V Lerma, Javed Butler, Stephan von Haehling, Scott H Adler, June Zhao, Bhupinder Singh, Philip T Lavin, Peter A McCullough, Mikhail Kosiborod, David K Packham

Journal article  |  2019  |  CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

BACKGROUND AND OBJECTIVES: Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestina..

Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study

David K Packham, Ian R Fraser, Peter G Kerr, Karen R Segal

Journal article  |  2016  |  EBIOMEDICINE

BACKGROUND: Diabetic nephropathy is the most common cause of end stage renal failure. We assessed the safety, tolerability, and ex..

Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome

Tobias Felix Kropelin, Dick de Zeeuw, Frank Arjan Holtkamp, David Kenneth Packham, Hiddo JL Heerspink

Journal article  |  2016  |  NEPHROLOGY DIALYSIS TRANSPLANTATION

BACKGROUND: Albuminuria reduction due to angiotensin receptor blockers (ARBs) predicts subsequent renoprotection. Relating the ini..

A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial

Richard A Brigandi, Brendan Johnson, Coreen Oei, Mark Westerman, Gordana Olbina, Janak de Zoysa, Simon D Roger, Manisha Sahay, Nicholas Cross, Lawrence McMahon, Veerabhadra Guptha, Elena A Smolyarchuk, Narinder Singh, Steven F Russ, Sanjay Kumar

Journal article  |  2016  |  AMERICAN JOURNAL OF KIDNEY DISEASES

BACKGROUND: Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EP..

Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia

David K Packham, Mikhail Kosiborod

Journal article  |  2016  |  EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

INTRODUCTION: Hyperkalemia is a common electrolyte disorder that arises from dysfunctional homeostatic mechanisms or as a conseque..